| dc.contributor.author | Kumar, Bhupinder | |
| dc.contributor.author | Singh, Sandeep | |
| dc.contributor.author | Skvortsova, Ira | |
| dc.contributor.author | Kumar, Vinod | |
| dc.date.accessioned | 2017-08-01T08:41:36Z | |
| dc.date.available | 2017-08-01T08:41:36Z | |
| dc.date.issued | 2017 | |
| dc.identifier.citation | Kumar, B., Singh, S., Skvortsova, I., & Kumar, V. (2017). Promising targets in anti-cancer drug development: Recent updates. Current Medicinal Chemistry, 24(42), 4729-4752. doi: 10.2174/0929867324666170331123648 | en_US |
| dc.identifier.issn | 9298673 | |
| dc.identifier.uri | http://kr.cup.edu.in/handle/32116/245 | |
| dc.description.abstract | Cancer is a multifactorial disease and its genesis and progression are extremely complex. The biggest problem in the anticancer drug development is acquiring of multidrug resistance and relapse. Classical chemotherapeutics directly target the DNA of the cell, while the contemporary anticancer drugs involve molecular-targeted therapy such as targeting the proteins possessing abnormal expression inside the cancer cells. Conventional strategies for the complete eradication of the cancer cells proved ineffective. Targeted chemotherapy was successful in certain malignancies however, the effectiveness has often been limited by drug resistance and side effects on normal tissues and cells. Since last few years, many promising drug targets have been identified for the effective treatment of cancer. The current review article describes some of these promising anticancer targets that include kinases, tubulin, cancer stem cells, monoclonal antibodies and vascular targeting agents. In addition, promising drug candidates under various phases of clinical trials are also described. Multi-acting drugs that simultaneously target different cancer cell signaling pathways may facilitate the process of effective anti-cancer drug development. ? 2017 Bentham Science Publishers. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Bentham Science Publishers B.V. | en_US |
| dc.subject | Antineoplastic Agent | en_US |
| dc.subject | Cyclin Dependent Kinase | en_US |
| dc.subject | Monoclonal Antibody | en_US |
| dc.subject | Notch Receptor | en_US |
| dc.subject | Phosphotransferase | en_US |
| dc.subject | Phosphotransferase Inhibitor | en_US |
| dc.subject | Protein Tyrosine Kinase | en_US |
| dc.subject | Tubulin | en_US |
| dc.subject | Vascular Targeting Agent | en_US |
| dc.subject | Antineoplastic Agent | en_US |
| dc.subject | Protein Kinase | en_US |
| dc.subject | Protein Kinase Inhibitor | en_US |
| dc.subject | Cancer Resistance | en_US |
| dc.subject | Cancer Stem Cell | en_US |
| dc.subject | Drug Mechanism | en_US |
| dc.subject | Drug Targeting | en_US |
| dc.subject | Hedgehog Signaling | en_US |
| dc.subject | Human | en_US |
| dc.subject | Microtubule | en_US |
| dc.subject | Nf Kappa B Pathway | en_US |
| dc.subject | Phase 1 Clinical Trial (Topic) | en_US |
| dc.subject | Phase 2 Clinical Trial (Topic) | en_US |
| dc.subject | Phase 3 Clinical Trial (Topic) | en_US |
| dc.subject | Review | en_US |
| dc.subject | Signal Tr | en_US |
| dc.title | Promising targets in anti-cancer drug development: Recent updates | en_US |
| dc.type | Review | en_US |
| dc.identifier.doi | 10.2174/0929867324666170331123648 | |
| dc.identifier.url | http://www.eurekaselect.com/151255/article | |
| dc.title.journal | Current Medicinal Chemistry | |
